European drug firms likely will not get a boost in OTC sales as the region’s economic crisis forces governments to cut health care spending, but should instead prioritize Rx-to-OTC switches and product development as growth drivers, says former Pfizer Inc. consumer business head Cavan Redmond.
As economic conditions constrict in EU member states, individual spending power also slows due to increased unemployment and salary reductions,...